-- Winners to be Announced on 30 May at the Prix Galien UK
Awards Ceremony in London
LONDON, May 16, 2024 /PRNewswire/ -- The Galien
Foundation, the premier global institution dedicated to honouring
innovators in life sciences, today announced the 2024 Prix Galien
UK Award candidates for "Best Biotechnology Product," "Best Digital
Health Solution," "Best Medical Technology," "Best Pharmaceutical
Product" and "Best Public Sector Innovation." Winners will be
selected by a committee of distinguished scientific leaders and
announced during the Prix Galien UK Awards Ceremony, on 30 May at
the Natural History Museum in London. To learn more and secure your ticket
to the event, please visit our website here.
"As Chair of the Prix Galien UK Committee, I am proud to
announce the exceptional candidates across five distinguished
categories. These individuals and organisations embody the essence
of healthcare excellence, demonstrating profound dedication to
improving the human condition. Their remarkable contributions serve
as beacons of hope and progress, shaping the future of healthcare
for generations to come," said Professor Sir Munir Pirmohamed, David Weatherall Chair of
Medicine at the University of Liverpool
and the NHS Chair of Pharmacogenetics, Chair of the Prix Galien UK
Committee.
The award committee is reviewing what was innovative during the
product's scientific development, application, or clinical utility,
what was learned for the future of biomedical science from the
product's introduction to the clinic, and what impact the product
has had on human health.
"Each candidate stands as a testament to the relentless pursuit
of health innovation and the enduring spirit of human achievement.
We congratulate all individuals behind these life-changing products
who have pledged their commitment to a healthier future for all,"
said Bruno Cohen, Chairman of The
Galien Foundation.
The 2024 Prix Galien UK Award Candidates are as follows:
Best Biotechnology Product (Candidates)
argenx
|
VYVGART®
|
PTC
Therapeutics
|
Upstaza™
|
Takeda UK
Ltd.
|
Qdenga
|
Best Digital Health Solution (Candidates)
Bayer x Ada
Health
|
AI-powered Self-care
for Women's Intimate Health
|
Behold.ai Technologies
Limited
|
Red dot® CTH
V1
|
BRAINOMIX
|
Brainomix 360
Stroke
|
C the Signs
|
C the Signs AI Cancer
Prediction Platform
|
C2-Ai
|
C2-Ai Elective Waiting
List Risk Stratification and Prioritisation System
|
Clarivate
|
Patient
Connect
|
Clinitouch by Spirit
Health
|
Clinitouch
|
Docobo Ltd
|
DOC@HOME® remote
patient monitoring/CAREPORTAL® class IIa medical monitoring
device
|
Feedback
Medical
|
Bleepa
|
Flexicare UK
Ltd
|
Flexicare
|
General Electric
HealthCare
|
Intelligent RT
(iRT)
|
ICE Creates
Ltd
|
Best-You
|
Islacare
|
Isla - Visual Record
platform
|
Medable
|
Medable Evidence
Generation Platform
|
Molnlycke Health
Care
|
Wound Talks: 10
Essentials of Wound Healing (an educational tool for healthcare
professionals)
|
Tympa Health
Technologies Ltd
|
The Tympa
system
|
uMotif®
limited
|
uMotif: A
Transformative, Patient-Focused Data Capture Platform to Power
Clinical Research
|
Best Medical Technology (Candidates)
Centinel Spine,
LLC
|
prodisc®
|
Christie Medical
Holdings, Inc.
|
VeinViewer® Imaging
System
|
CMR Surgical
|
Versius® Surgical
Robotic System
|
Germitec
|
Yuvee®
|
Insulet
Corporation
|
Omnipod® 5 Automated
Insulin Delivery System
|
iSTAR
Medical
|
MINIject®
|
Ideal Medical Solutions
Limited
|
EchoLaser SoracteLite
TPLA
|
MED-EL
|
ADHEAR
|
Novai Ltd
|
Detection of Apoptosing
Retinal Cells (DARC)
|
Owkin
|
MSIntuit®
CRC
|
Panakeia Technologies
Ltd.
|
PANProfiler Breast (ER,
ER, HER2) or Breast Profiler
|
Polynovo UK
Ltd.
|
NovoSorb®
BTM
|
PolyPhotonix
Ltd
|
Noctura 400
|
Roche Diagnostics
Ltd.
|
cobas® SARS-CoV-2
Test
|
Smith & Nephew
Medical Ltd.
|
Negative Pressure Wound
Therapy
|
Wellvii
|
Blood Pressure Finger
Cuff
|
Best Pharmaceutical Product (Candidates)
Amicus
Therapeutics
|
Pombiliti® with
Opfolda® (PomOp)
|
Boehringer
Ingelheim
|
Ofev®
|
CSL Seqirus
|
Adjuvanted Quadrivalent
Influenza Vaccine▼
(aQIV)
|
Deciphera
Pharmaceuticals
|
Qinlock®▼
(ripretinib)
|
Novartis
|
PLUVICTO
|
Pharmasset /
Gilead
|
SOVALDI®
(Sofosbuvir)
|
Best Public Sector Innovation (Candidates)
Cognitant Group
Ltd
|
My Stroke
Companion
|
University College
London (UCL)
|
Institute for Global
Health
|
University of
Oxford
|
PRINCIPLE and PANORAMIC
Trials
|
The Prix Galien UK Awards launched in 1990 and have been awarded
to 51 products since its inception. Winners are selected every two
years by the Prix Galien UK Awards Committee, which comprises 14
experts in the field, and includes a number of the UK's leading
luminaries in healthcare. The distinguished panel is guided by the
conviction that acknowledging research-driven innovation is key to
the improvement of healthcare in the UK and human health,
globally.
During the ceremony, the 2024 Prix Galien UK Lifetime
Achievement Award will be bestowed upon Professor Sir John Bell, President, CEO of the Ellison
Institute of Technology Oxford - Emeritus Regius Professor of
Medicine, University of Oxford. Sir
John will deliver the keynote address, "Supporting the life
sciences industry in the UK."
Prix Galien UK Awards Committee 2024
Pr Sir Munir PIRMOHAMED
David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of
Pharmacogenetics
Committee Chair
Pr Jane ADAM
Honorary Professor, University of Exeter, Consultant Radiologist, St George's
Hospital London and former Chair Technology appraisal committee,
NICE
Pr Bruce CAMPBELL
Past Chair NICE
Interventional Procedures and Medical Technologies
Advisory Committees; Honorary Vascular Consultant and Professor,
Exeter
Dr Stephanie KUKU
Chief Knowledge Officer, Conceivable Life Sciences, Senior
Consultant, Hadrian Health, Board Member Equinox and Board
Trustee, The Kings Fund
Pr Sudhesh KUMAR
Vice President (Health), University of
Warwick and President of Association of Innovation, Research
and Technology Organisations, UK (AIRTO)
Pr Sir Robert LECHLER
Emeritus Senior Vice President (Health), King's College London
Pr Andrew MORRIS
Director, Health Data Research UK & Professor of Medicine and
Vice Principal Data Science, University of
Edinburgh
Dame June RAINE
Chief Executive, Medicines and Healthcare products Regulatory
Agency
Pr Duncan RICHARDS
Professor of Clinical Therapeutics, University
of Oxford
Pr Liam SMEETH
Professor of Clinical Epidemiology and Director of the London
School of Hygiene and Tropical Medicine
Pr Rosalind SMYTH
Professor of Child Health, UCL Great Ormond St. Institute
of Child Health, Vice Dean Research in the UCL Faculty of
Population Health Sciences & Vice President (Clinical) UK
Academy of Medical Sciences
Dr Lauren WALKER
Senior Clinical Lecturer in Clinical Pharmacology &
Therapeutics and Internal Medicine, University
of Liverpool
Pr Moira WHYTE
Sir John Crofton Professor of
Respiratory Medicine, University of
Edinburgh
About The Galien Foundation
The Galien Foundation
fosters, recognises and rewards excellence in scientific
innovation to improve the state of human health. Our vision is to
be the catalyst for the development of the next generation of
innovative treatments and technologies that will impact the state
of medical practice and save lives.
The Foundation oversees and directs activities in the UK for the
Prix Galien, an international awards programme dedicated to
progress through innovative medicines development, with chapters in
14 countries, Africa and an
inaugural chapter established in India in 2024. The Prix Galien was created in
1970 by Roland Mehl in honour of
Galien, the father of medical science and modern pharmacology.
Worldwide, the Prix Galien is regarded as the equivalent of the
Nobel Prize in biopharmaceutical research.
For more information, visit www.galienfoundation.org.
Follow the Foundation on social media:
https://www.facebook.com/GalienFoundation/
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/
Media Contact (UK):
Julian Tyndale-Biscoe
Finn Partners
Julian.Tyndale-biscoe@finnpartners.com
+44 20 3217 7060
Media Contact (Global):
Kara
Bradley
Finn Partners
Kara.Bradley@finnpartners.com
646-213-7243
Logo -
https://mma.prnewswire.com/media/2414480/GalienLogo_800x300_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/the-galien-foundation-announces-2024-prix-galien-uk-award-candidates-for-best-biotechnology-product-best-digital-health-solution-best-medical-technology-best-pharmaceutical-product-and-best-public-sector-innovation-302147180.html